Țară: Australia
Limbă: engleză
Sursă: Department of Health (Therapeutic Goods Administration)
ursodeoxycholic acid, Quantity: 50 mg/mL
Dr Falk Pharma Australia Pty Ltd
Ursodeoxycholic acid
Oral Liquid, suspension
Excipient Ingredients: benzoic acid; glycerol; citric acid; sodium chloride; purified water; sodium citrate dihydrate; propylene glycol; xylitol; sodium cyclamate; microcrystalline cellulose; carmellose sodium; Flavour
Oral
250ml
(S4) Prescription Only Medicine
Treatment of chronic cholestatic liver diseases.
Visual Identification: White, homogenous suspension containing small air bubbles.; Container Type: Bottle; Container Material: Glass Type III Coloured; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2006-11-15
_Consumer Medicine Information _ _URSO_ _ _ URSO URSODEOXYCHOLIC ACID CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about URSO. It does not contain all of the available information. Reading this leaflet does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking URSO against the benefits they expect it will have for you or your child. IF YOU HAVE ANY CONCERNS ABOUT TAKING URSO, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You or your child may want to read it again. WHAT URSO IS USED FOR URSO contains ursodeoxycholic acid. Ursodeoxycholic acid is a bile acid, which may have a protective effect on the liver by reducing the absorption of other potentially toxic bile salts. URSO may be used to treat liver diseases such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cystic fibrosis (CF)-related cholestasis. However, your doctor may prescribe this medicine for another use. IF YOU OR YOUR CHILD WANTS MORE INFORMATION, ASK YOUR DOCTOR. ASK YOUR DOCTOR IF YOU OR YOUR CHILD HAS ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU OR YOUR CHILD. URSO is not addictive. URSO does not cause any negative effect on driving ability and operating machinery. BEFORE YOU OR YOUR CHILD TAKES URSO URSO is not suitable for everyone. _WHEN YOU OR YOUR CHILD MUST NOT TAKE _ _URSO _ DO NOT TAKE URSO IF: • you or your child is allergic to ursodeoxycholic acid or any other ingredients listed at the end of this leaflet • you or your child has a bile duct or gall bladder that is swollen, painful or blocked • the packaging is torn or shows signs of tampering • the capsules, tablets or suspension, look to be deteriorating in any way • the expiry date (EXP) printed on the pack has passed, as it may not work as well • do not use URSO suspension after 4 months of opening the bottle IF YOU ARE NOT SURE WHETHER YOU OR YOUR CHILD SHOULD START TAKIN Citiți documentul complet
_Product Information _ _ _ _URSO_ _®_ 1 PRODUCT INFORMATION URSO ® (Ursodeoxycholic Acid) NAME OF THE MEDICINE The chemical structure of ursodeoxycholic acid is as follows: CAS number: 128-13-2 DESCRIPTION Ursodeoxycholic acid (UDCA) is a white or almost white powder. It is practically insoluble in water, readily soluble in alcohol, sparingly soluble in acetone, in chloroform and in ether. It melts at 200 - 204ºC. The IUPAC chemical name of UDCA is 3 α , 7ß-dihydroxy-5-cholan-24-oic acid. URSO Capsule contains UDCA 250 mg, maize starch, colloidal anhydrous silica, magnesium stearate, gelatin, titanium dioxide, sodium lauryl sulfate and purified water. URSO Suspension contains UDCA 50 mg/mL, benzoic acid, purified water, xylitol, glycerol, Avicel RC-591, propylene glycol, sodium citrate dihydrate, sodium cyclamate, citric acid, sodium chloride and 87017 lemon flavour. URSO Tablet contains UDCA 500 mg, magnesium stearate, polysorbate 80, povidone, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, purified talc, hypromellose and macrogol 6000. PHARMACOLOGY PHARMACODYNAMIC PROPERTIES The mechanism of action of UDCA in liver and cholestatic disorders has not yet been explained totally. However, UDCA alters bile acid composition, resulting in _Product Information _ _ _ _URSO_ _®_ 2 increases in the concentration of UDCA and decreases in the concentrations of the more hydrophobic and potentially toxic bile acids, cholic and chenodeoxycholic acids. UDCA also has a choleretic effect, resulting in increased bile acid output and bile flow. There is some evidence for immunological effects, including a reduction of abnormal expression of HLA Class I antigens on hepatocytes and a suppression of immunoglobulin and cytokine production. PHARMACOKINETIC PROPERTIES UDCA occurs naturally in the body. After oral administration of a single 500 mg dose of UDCA to healthy volunteers, peak plasma concentrations were 2.7 to 6.3 μg/mL. T max occurs at 60 minutes and a second peak plasma concentration occurs at 18 Citiți documentul complet